Medpace Holdings, Inc. (MEDP) stock
MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 22, 2026Score 14/3042% above fair value
$646.87−6.22 (-0.95%)
Close on Nov 18, 2026Market cap $18.09BP/E 35.9Yield –
Medpace pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Medpace's pe ratio was 39.0× on Nov 11, 2026, against 41.4× a year earlier. Over the last 5 years it ranged from 22.5× to 45.5×, with a median of 32.2×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 39.0× | −0.3 |
| 2025 | Dec 31, 2025 | 39.3× | +10.2 |
| 2024 | Dec 31, 2024 | 29.1× | −6.8 |
| 2023 | Dec 29, 2023 | 35.9× | +3.3 |
| 2022 | Dec 30, 2022 | 32.6× | −12.5 |
| 2021 | Dec 31, 2021 | 45.1× | +2.5 |
| 2020 | Dec 31, 2020 | 42.6× | +8.7 |
| 2019 | Dec 31, 2019 | 33.9× | +2.2 |
| 2018 | Dec 31, 2018 | 31.7× | −21.6 |
| 2017 | Dec 29, 2017 | 53.3× | −247.3 |
| 2016 | Dec 30, 2016 | 300.6× | – |
See a number that looks wrong?